

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

**1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Mometasone / Clotrimazole / Gentamicin Formulation

Other means of identification : MOMETAMAX OINTMENT (52269)

**Manufacturer or supplier's details**

Company : MSD

Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

**2. HAZARDS IDENTIFICATION****GHS Classification**

Reproductive toxicity : Category 1A

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 2

**GHS label elements**

Hazard pictograms



Signal word : Danger

Hazard statements : H360D May damage the unborn child.  
H400 Very toxic to aquatic life.  
H411 Toxic to aquatic life with long lasting effects.

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version 8.0      Revision Date: 2025/06/17      SDS Number: 412818-00026      Date of last issue: 2024/12/03  
Date of first issue: 2015/12/14

**Precautionary statements**

**Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	$\geq 60$ - $\leq 100$
clotrimazole	23593-75-1	$\geq 0.25$ - $< 2.5$
Gentamicin	1403-66-3	$\geq 0.3$ - $< 1$
Mometasone	83919-23-7	$\geq 0.025$ - $< 0.25$

**4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

If swallowed	: Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: May damage the unborn child.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**7. HANDLING AND STORAGE**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Components with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
White mineral oil (petroleum)	8042-47-5	NAB (Mist)	5 mg/m <sup>3</sup>	ID OEL
		PSD (Mist)	10 mg/m <sup>3</sup>	ID OEL
		TWA (Inhal-)	5 mg/m <sup>3</sup>	ACGIH

# Mometasone / Clotrimazole / Gentamicin Formulation

Version 8.0      Revision Date: 2025/06/17      SDS Number: 412818-00026      Date of last issue: 2024/12/03  
Date of first issue: 2015/12/14

		able particulate matter)		
clotrimazole	23593-75-1	TWA	0.2 mg/m <sup>3</sup> (OEB 2)	Internal
Gentamicin	1403-66-3	TWA	0.1 mg/m <sup>3</sup> (OEB 2)	Internal
	Further information: OTO			
Mometasone	83919-23-7	TWA	1 µg/m <sup>3</sup> (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

## Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	: suspension
Colour	: white to off-white
Odour	: oily
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

---

Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	Not applicable

---

**10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	--

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****White mineral oil (petroleum):**

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhalation toxicity
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

**clotrimazole:**

Acute oral toxicity	: LD50 (Rat): 708 mg/kg LD50 (Mouse): 761 mg/kg LD50 (Rabbit): > 1,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 0.73 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Mouse): 923 mg/kg

**Gentamicin:**

Acute oral toxicity	: LD50 (Rat): 8,000 - 10,000 mg/kg LD50 (Mouse): 10,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 0.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	: LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous  LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular  LDLo (Monkey): 30 mg/kg Application Route: Intravenous



**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

**II****Mometasone:**

Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	:	LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.  LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute toxicity (other routes of administration)	:	LD50 (Rat): 300 mg/kg Application Route: Subcutaneous Symptoms: Breathing difficulties

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Species	:	Rabbit
Result	:	No skin irritation

**clotrimazole:**

Species	:	Rabbit
Result	:	No skin irritation

**Gentamicin:**

Species	:	Rabbit
Result	:	Mild skin irritation

**Mometasone:**

Species	:	Rabbit
Result	:	No skin irritation

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Species	:	Rabbit
---------	---	--------

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

**Result** : No eye irritation

**clotrimazole:**

**Species** : Rabbit  
**Result** : Mild eye irritation

**Gentamicin:**

**Species** : Rabbit  
**Result** : Mild eye irritation

**Mometasone:**

**Species** : Rabbit  
**Result** : No eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

**Test Type** : Buehler Test  
**Exposure routes** : Skin contact  
**Species** : Guinea pig  
**Result** : negative

**Gentamicin:**

**Remarks** : No data available

**Mometasone:**

**Test Type** : Maximisation Test  
**Exposure routes** : Dermal  
**Species** : Guinea pig  
**Assessment** : Does not cause skin sensitisation.  
**Result** : negative  
**Remarks** : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.

**Germ cell mutagenicity**

Not classified based on available information.

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

**Components:****White mineral oil (petroleum):**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

**clotrimazole:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosome aberration test in vitro Result: negative  Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Oral Result: negative  Test Type: Mammalian spermatogonial chromosome aberration test (in vivo) Species: Hamster Result: negative
Germ cell mutagenicity - Assessment	:	Weight of evidence does not support classification as a germ cell mutagen.

**Gentamicin:**

Genotoxicity in vitro	:	Test Type: In vitro mammalian cell gene mutation test Result: negative  Test Type: Chromosome aberration test in vitro Result: equivocal
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Intravenous injection

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

Result: negative

**Mometasone:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Test Type: Chromosomal aberration  
Species: Rat  
Cell type: Bone marrow  
Result: negative

Test Type: unscheduled DNA synthesis assay  
Species: Rat  
Cell type: Liver cells  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****White mineral oil (petroleum):**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 24 Months
Result	: negative

**clotrimazole:**

Species	: Rat
Application Route	: Oral

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

Exposure time	: 78 weeks
Result	: negative

**Gentamicin:**

Carcinogenicity - Assessment	: No data available
------------------------------	---------------------

**Mometasone:**

Species	: Rat
Application Route	: Inhalation
Exposure time	: 2 Years
Dose	: 0.067 mg/kg body weight
Result	: negative

Species	: Mouse
Application Route	: Inhalation
Exposure time	: 19 Months
Dose	: 0.160 mg/kg body weight
Result	: negative

**Reproductive toxicity**

May damage the unborn child.

**Components:****White mineral oil (petroleum):**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

**clotrimazole:**

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: LOAEL: 50 mg/kg body weight Result: Effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

	<p>Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 50 mg/kg body weight Result: Embryo-foetal toxicity, No teratogenic effects</p> <p>Test Type: Embryo-foetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 200 mg/kg body weight Result: No effects on foetal development</p> <p>Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 180 mg/kg body weight Result: No effects on foetal development</p>
Reproductive toxicity - Assessment	: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

**Gentamicin:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Fertility: NOAEL: 20 mg/kg body weight Result: No significant adverse effects were reported
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: 3.6 mg/kg body weight Result: No embryo-foetal toxicity
	<p>Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-foetal toxicity</p> <p>Test Type: Embryo-foetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.</p> <p>Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 50 mg/kg body weight</p>

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

	Result: foetal mortality, No malformations were observed.
Reproductive toxicity - Assessment	: Positive evidence of adverse effects on development from human epidemiological studies.
<b>Mometasone:</b>	
Effects on fertility	: Test Type: Fertility Species: Rat Application Route: Subcutaneous Fertility: NOAEL: 0.015 mg/kg body weight Symptoms: Reduced embryonic survival, Reduced foetal weight Result: No effects on fertility, Effect on reproduction capacity
Effects on foetal development	: Test Type: Embryo-foetal development Species: Mouse Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmental toxicity  Test Type: Embryo-foetal development Species: Rat Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight Result: Embryo-foetal toxicity  Test Type: Embryo-foetal development Species: Rabbit Application Route: Dermal Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.  Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Effects on newborn  Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.
Reproductive toxicity - Assessment	: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

**STOT - single exposure**

Not classified based on available information.

**Components:****Mometasone:**

Remarks	: Based on available data, the classification criteria are not met.
---------	---

**STOT - repeated exposure**

Not classified based on available information.

**Components:****clotrimazole:**

Target Organs	: Liver, Kidney, Adrenal gland
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Gentamicin:**

Target Organs	: Kidney, inner ear
Assessment	: Causes damage to organs through prolonged or repeated exposure.

**Mometasone:**

Exposure routes	: inhalation (dust/mist/fume)
Target Organs	: Immune system, Liver, Kidney, Skin
Assessment	: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****White mineral oil (petroleum):**

Species	: Rat
LOAEL	: 160 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Species	: Rat
LOAEL	: >= 1 mg/l
Application Route	: inhalation (dust/mist/fume)
Exposure time	: 4 Weeks
Method	: OECD Test Guideline 412

**clotrimazole:**

Species	: Rabbit
LOAEL	: 5 - 40 mg/kg



**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

Application Route	: Skin contact
Exposure time	: 3 Weeks
Target Organs	: Skin
Symptoms	: Oedema, Fissuring, Necrosis, Redness

Species	: Rat
LOAEL	: 10 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Liver, Kidney, Adrenal gland

Species	: Dog
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 6 - 12 Months
Target Organs	: Adrenal gland
Symptoms	: Salivation, Lachrymation, Vomiting

**Gentamicin:**

Species	: Dog
LOAEL	: 3 mg/kg
Application Route	: Intramuscular
Exposure time	: 12 Months
Target Organs	: Kidney
Symptoms	: Vomiting, Salivation

Species	: Monkey
LOAEL	: 50 mg/kg
Application Route	: Subcutaneous
Exposure time	: 3 Weeks
Target Organs	: Kidney, inner ear

Species	: Monkey
LOAEL	: 6 mg/kg
Application Route	: Intramuscular
Exposure time	: 3 Weeks
Target Organs	: Blood, Kidney, inner ear, Liver

Species	: Rat
NOAEL	: 5 mg/kg
LOAEL	: 10 mg/kg
Application Route	: Intramuscular
Exposure time	: 52 Weeks
Target Organs	: Kidney, Blood

Species	: Rat
NOAEL	: 12.5 mg/kg
LOAEL	: 50 mg/kg
Application Route	: Intramuscular
Exposure time	: 13 Weeks

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

|| Target Organs : Kidney

**Mometasone:**

|| Species : Rat  
|| NOAEL : 0.005 mg/kg  
|| LOAEL : 0.3 mg/kg  
|| Application Route : Oral  
|| Exposure time : 30 d  
|| Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

|| Species : Dog  
|| NOAEL : 0.5 mg/kg  
|| Application Route : Oral  
|| Exposure time : 30 d  
|| Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

|| Species : Rat  
|| NOAEL : 0.00013 mg/l  
|| Application Route : inhalation (dust/mist/fume)  
|| Exposure time : 90 d  
|| Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

|| Species : Dog  
|| NOAEL : 0.0005 mg/l  
|| Application Route : inhalation (dust/mist/fume)  
|| Exposure time : 90 d  
|| Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

**Aspiration toxicity**

Not classified based on available information.

**Components:****Mometasone:**

|| Not applicable

**Experience with human exposure****Components:****clotrimazole:**

|| Skin contact : Symptoms: Rash, Itching, Blistering, Oedema, Redness  
|| Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea

**Gentamicin:**

|| Ingestion : Target Organs: Kidney  
|| Target Organs: inner ear  
|| Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

# Mometasone / Clotrimazole / Gentamicin Formulation

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

|| deafness

## Mometasone:

Inhalation	:	Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion
Skin contact	:	Symptoms: Dermatitis, Itching

## Further information

## Components:

## Mometasone:

|| Remarks : Dermal absorption possible

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

## Components:

### White mineral oil (petroleum):

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity)	:	NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l Exposure time: 28 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 1,000 mg/l Exposure time: 21 d

### clotrimazole:

Toxicity to fish	:	LC50 (Brachydanio rerio (zebrafish)): > 0.29 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.02 mg/l Exposure time: 48 h
Toxicity to algae/aquatic	:	EC50 (Desmodesmus subspicatus (green algae)): 0.268 mg/l

# Mometasone / Clotrimazole / Gentamicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
8.0	2025/06/17	412818-00026	2024/12/03
			Date of first issue: 2015/12/14

plants	Exposure time: 72 h
	NOEC (Desmodesmus subspicatus (green algae)): 0.017 mg/l
	Exposure time: 72 h
M-Factor (Acute aquatic toxicity)	: 10
Toxicity to fish (Chronic toxicity)	: NOEC (Oncorhynchus mykiss (rainbow trout)): 0.025 mg/l
	Exposure time: 32 d
	Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 0.01 mg/l
	Exposure time: 21 d
	Method: OECD Test Guideline 211
M-Factor (Chronic aquatic toxicity)	: 10
Toxicity to microorganisms	: EC50: > 10,000 mg/l
	Exposure time: 3 h
	Test Type: Respiration inhibition
	Method: OECD Test Guideline 209

## Gentamicin:

Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 86 mg/l
	Exposure time: 48 h
	Method: OECD Test Guideline 202
	LC50 (Americamysis): 30 mg/l
	Exposure time: 96 h
	Method: US-EPA OPPTS 850.1035
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
	NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l
	Exposure time: 72 h
	Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 100

# Mometasone / Clotrimazole / Gentamicin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

M-Factor (Chronic aquatic toxicity)	:	1
Toxicity to microorganisms	:	EC50: 288.7 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

## Mometasone:

Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): 0.11 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility  LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l Exposure time: 7 d Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility  EC50 (Americamysis): > 5 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.34 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility
M-Factor (Chronic aquatic toxicity)	:	100
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version 8.0	Revision Date: 2025/06/17	SDS Number: 412818-00026	Date of last issue: 2024/12/03 Date of first issue: 2015/12/14
----------------	------------------------------	-----------------------------	---

NOEC: 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility

**Persistence and degradability****Components:****White mineral oil (petroleum):**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 31 %  
Exposure time: 28 d

**clotrimazole:**

Stability in water : Hydrolysis: 50 %(242 d)

**Gentamicin:**

Biodegradability : Result: rapidly degradable  
Biodegradation: 100 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

**Mometasone:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)  
Method: OECD Test Guideline 111

**Bioaccumulative potential****Components:****Gentamicin:**

Partition coefficient: n-  
octanol/water : log Pow: < -2

**Mometasone:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 107.1  
Method: OECD Test Guideline 305

Partition coefficient: n-  
octanol/water : log Pow: 4.68

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

**Mobility in soil****Components:****Mometasone:**

Distribution among environ- : log Koc: 4.02  
mental compartments

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-  
dling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(clotrimazole, Gentamicin)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(clotrimazole, Gentamicin)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964  
aircraft)

Packing instruction (passen- : 964  
ger aircraft)

Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,  
N.O.S.  
(clotrimazole, Gentamicin)

**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

Class	:	9
Packing group	:	III
Labels	:	9
EmS Code	:	F-A, S-F
Marine pollutant	:	yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

**15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use	:	Not applicable
Prohibited substances	:	Not applicable
Restricted substances	:	Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

**The components of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

**16. OTHER INFORMATION**



**Mometasone / Clotrimazole / Gentamicin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

Revision Date : 2025/06/17

**Further information**Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
ID OEL : Indonesia. Occupational Exposure LimitsACGIH / TWA : 8-hour, time-weighted average  
ID OEL / NAB : Long term exposure limit  
ID OEL / PSD : Short term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

**Mometasone / Clotrimazole / Gentamicin For-  
mulation**

Version	Revision Date:	SDS Number:	Date of last issue: 2024/12/03
8.0	2025/06/17	412818-00026	Date of first issue: 2015/12/14

---

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ID / EN